• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cingulate Inc. - Warrants (NQ: CINGW )

    0.0385 -0.0065 (-14.44%)
    Streaming Delayed Price Updated: 3:49 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12,435
    Open 0.0440
    Bid (Size) 0.0320 (5)
    Ask (Size) 0.0449 (9)
    Prev. Close 0.0450
    Today's Range 0.0320 - 0.0450
    52wk Range 0.0070 - 0.1800
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
    Data Accepted as Finalist for First Annual Poster Awards 
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
    From Cingulate Inc.
    Via GlobeNewswire

    Performance

    YTD
    +28.76%
    +28.76%
    1 Month
    -46.53%
    -46.53%
    3 Month
    +381.25%
    +381.25%
    6 Month
    +76.61%
    +76.61%
    1 Year
    -59.43%
    -59.43%

    More News

    Read More
    Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate to Present at 13th Annual LD Micro Invitational
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate, Indegene to Participate in Benzinga All Live Access Event
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate to Participate in Benzinga All Live Access Event
    From Cingulate Inc.
    Via GlobeNewswire
    Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
    From Cingulate Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.